PCRXPacira BioSciences, Inc.
Pharmaceutical Preparations
- Revenue
- $726M
- 3.6% YoY
- Operating margin
- 2.6%
- 125% YoY
- EBITDA
- $110M
- 1936% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 1.4×
- $157M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear22× net incomeCash flow under 80% of net income
- Dilutive SBCClear8% of revenueOver 10% of revenue
- Payouts exceed cash flowClear98% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear2% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $542M | $667M | $675M | $701M | $726M | 3.6% |
| Operating income | $90M | $60M | $88M | −$73M | $19M | 126% |
| Net income | $42M | $16M | $42M | −$100M | $7M | 107% |
| Operating cash flow | $126M | $145M | $155M | $189M | $152M | 20% |
| Capex | $46M | $30M | $15M | $11M | $15M | 44% |
| Stock-based comp | $42M | $48M | $48M | $51M | $58M | 12% |
| Buybacks | — | $0 | $0 | $25M | $148M | 493% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $218K · 1
- Net
- −$218K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 43 | 107 |
| FY2024 | — | — | 31 | 82 |
| FY2023 | — | — | 56 | 80 |
| FY2022 | — | — | 65 | 79 |
| FY2021 | — | — | 101 | 89 |